We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+14.07%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$705M
AUM Growth
+$41.3M
Cap. Flow
+$7.11M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.32%
Holding
99
New
15
Increased
51
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$24.2M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$16.8M
3
CLSD
Clearside Biomedical
CLSD
+$13.9M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$8.94M
5
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$8.79M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$23.9M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10.6M
3
CELG
Celgene Corp
CELG
+$10M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$9.47M
5
RMTI icon
Rockwell Medical
RMTI
+$8.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
26
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$9.4M 1.33%
758,290
+4,902
+0.7% +$61.3K
PTLA
27
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$9.35M 1.33%
396,000
-304,000
-43% -$7.51M
DVAX
28
DELISTED
Dynavax Technologies
DVAX
$9.26M 1.31%
635,000
-340,000
-35% -$5.81M
RLYP
29
DELISTED
RELYPSA INC COM
RLYP
$8.32M 1.18%
+450,000
New +$7.9M
WVE icon
30
Wave Life Sciences
WVE
$1.11B
$8.16M 1.16%
394,407
+2,328
+0.6% +$36.3K
SGMO
31
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.12M 1.15%
+1,402,331
New +$8.94M
DXCM icon
32
DexCom
DXCM
$28.8B
$7.93M 1.13%
400,000
-212,000
-35% -$3.61M
ACHN
33
DELISTED
Achillion Pharmaceuticals
ACHN
$7.85M 1.11%
1,006,128
+506,128
+101% +$4.34M
SYNH
34
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$7.63M 1.08%
+200,000
New +$8.79M
MCRB icon
35
Seres Therapeutics
MCRB
$46.3M
$7.35M 1.04%
12,653
+153
+1% +$89.8K
ADXS
36
DELISTED
Advaxis Inc
ADXS
$6.55M 0.93%
53,987
+654
+1% +$83.8K
AGEN
37
Agenus
AGEN
$329M
$6.39M 0.91%
80,405
+974
+1% +$75.9K
SCTL
38
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$6.19M 0.88%
867,791
-1,909
-0.2% -$12.8K
FWP
39
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$6.16M 0.87%
48,454
+587
+1% +$79.2K
CRBP icon
40
Corbus Pharmaceuticals
CRBP
$168M
$5.98M 0.85%
+66,667
New +$5.23M
RARE icon
41
Ultragenyx Pharmaceutical
RARE
$2.56B
$5.42M 0.77%
110,842
+1,342
+1% +$86.8K
COLL icon
42
Collegium Pharmaceutical
COLL
$1.17B
$5.4M 0.77%
455,515
+5,515
+1% +$91.1K
PFNX
43
DELISTED
Pfenex Inc.
PFNX
$5.29M 0.75%
632,559
+7,659
+1% +$61.9K
DERM
44
DELISTED
Dermira, Inc.
DERM
$5.03M 0.71%
172,083
+2,083
+1% +$57.5K
XLRN
45
DELISTED
Acceleron Pharma
XLRN
$4.33M 0.61%
127,451
-72,549
-36% -$2.36M
AGRX
46
DELISTED
Agile Therapeutics
AGRX
$4.29M 0.61%
282
+3
+1% +$41.1K
ATRA icon
47
Atara Biotherapeutics
ATRA
$73.6M
$4.2M 0.6%
7,458
+1,458
+24% +$700K
IOVA icon
48
Iovance Biotherapeutics
IOVA
$2.09B
$4.1M 0.58%
505,941
+6,126
+1% +$38.5K
CTMX icon
49
CytomX Therapeutics
CTMX
$714M
$3.8M 0.54%
371,636
+613
+0.2% +$6.99K
INDP icon
50
Indaptus Therapeutics
INDP
$192M
$3.72M 0.53%
362
+5
+1% +$44.9K
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Cormorant Asset Management held 99 positions worth $705M, up 6.2% from $664M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Cormorant Asset Management's Q2 2016 filing shows 15 new, 51 increased, 12 reduced and 16 closed positions. Its largest new stake was Theravance Biopharma: 1,118,372 shares worth $25.4M. The largest sale was Alkermes, an estimated $23.9M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier.

  • Cormorant Asset Management's largest Q2 2016 buy was Theravance Biopharma: 1,118,372 shares worth $25.4M.
  • Cormorant Asset Management added most to Minerva Neurosciences in Q2 2016, an estimated $8.32M increase.
  • Cormorant Asset Management's biggest Q2 2016 reduction was Neurocrine Biosciences, cutting an estimated $9.47M.
  • Cormorant Asset Management fully exited Alkermes in Q2 2016, selling an estimated $23.9M.
  • Cormorant Asset Management's ten largest holdings make up 40% of its $705M portfolio in Q2 2016.
  • Cormorant Asset Management opened 15 new positions and closed 16 in Q2 2016.
  • Cormorant Asset Management's portfolio value rose 6.2% quarter-over-quarter to $705M.

Based on Cormorant Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.